drugset / Trial / NCT01619462

Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children

NCT01619462

RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to evaluate the safety and immunogenicity of the 10-valent and 13-valent pneumococcal conjugate vaccines when administered in an accelerated schedule in Papua New Guinean children, who experience early dense upper respiratory tract colonisation with a broad range of pneumococcal serotypes, and to compare antibody titres following a booster dose of polysaccharide vaccine at 9 months with those children who received no booster at the same age.

Timeline

Start
2011-11
Primary completion
2014-04
Completion
2016-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Prevnar 13 Vaccine
Subject Synflorix Vaccine